



Anti-FUT3 (clone BR 96)-Mc-Dox ADC

Cat. No: ADC-W-463

Antibody clone #: BR 96

PRODUCT INFORMATION

This ADC product is comprised of an Anti-FUT3 antibody (clone BR 96) conjugated via a Mc linker to Dox. The Dox is targeted to certain cancers by immunorecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Dox binds to DNA, causes DNA damage.

ADC Target

Name:	FUT3
Alternative Names:	FUT3; fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group); LE; Les; FT3B; CD174; FucT-III; galactoside 3(4)-L-fucosyltransferase; Lewis FT; fucosyltransferase III; alpha-(1,3/1,4)-fucosyltransferase; blood group Lewis alpha-4-f
Target Entrez Gene ID:	2525
Target UniProt ID:	A8K737
Overview:	The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and circulate in body fluids. The glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and bacterial adhesion. They are secondarily absorbed to red blood cells giving rise to their Lewis phenotype. This gene is a member of the fucosyltransferase family, which catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis. It encodes an enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Mutations in this gene are responsible for the majority of Lewis antigen-negative phenotypes. Multiple alternatively spliced variants, encoding the same protein, have been found for this gene.

ADC Antibody

Overview: Chimeric Anti-FUT3 Antibody, clone # BR 96

Clone #: BR 96

Species Reactivity: Human

ADC Linker

Name: Mc (maleimidocaproyl)

Description: Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

ADC payload drug

Name: Doxorubicin

Description: Doxorubicin is the generic name for the trade name drug, Adriamycin®, as well as, Rubex®, which is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called Topoisomerase that cancer cells need to divide and grow.

No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.